enGene Holdings Inc. (NASDAQ:ENGN) Receives $23.29 Average PT from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $23.2857.

A number of brokerages recently commented on ENGN. Raymond James Financial upgraded shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 target price (up from $30.00) on shares of enGene in a research note on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. Citigroup reissued a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Finally, Jefferies Financial Group initiated coverage on enGene in a report on Friday, January 30th. They issued a “buy” rating and a $28.00 price target on the stock.

enGene Price Performance

NASDAQ ENGN opened at $8.68 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. The stock has a market cap of $581.47 million, a price-to-earnings ratio of -3.79 and a beta of -0.29. The business has a 50 day simple moving average of $9.58 and a 200 day simple moving average of $8.04. enGene has a 52-week low of $2.65 and a 52-week high of $12.25.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). Analysts anticipate that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enGene

Institutional investors have recently bought and sold shares of the company. PFS Partners LLC boosted its position in enGene by 22.2% during the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares during the last quarter. Millennium Management LLC raised its holdings in shares of enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares during the last quarter. Raymond James Financial Inc. lifted its position in shares of enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Cresset Asset Management LLC bought a new stake in shares of enGene in the second quarter worth $36,000. Finally, Paloma Partners Management Co acquired a new position in enGene during the second quarter worth $38,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.